Abd El-Shafy, N., Deraz, H., Hussin, A., Assy, M. (2022). Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article. The Egyptian Journal of Hospital Medicine, 89(1), 5949-5954. doi: 10.21608/ejhm.2022.266823
Nema Abd El-Wanees Abd El-Shafy; Hamed Abd El-Aziz Deraz; Atef Goda Hussin; Mostafa Mohamed Assy. "Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article". The Egyptian Journal of Hospital Medicine, 89, 1, 2022, 5949-5954. doi: 10.21608/ejhm.2022.266823
Abd El-Shafy, N., Deraz, H., Hussin, A., Assy, M. (2022). 'Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article', The Egyptian Journal of Hospital Medicine, 89(1), pp. 5949-5954. doi: 10.21608/ejhm.2022.266823
Abd El-Shafy, N., Deraz, H., Hussin, A., Assy, M. Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article. The Egyptian Journal of Hospital Medicine, 2022; 89(1): 5949-5954. doi: 10.21608/ejhm.2022.266823
Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article
Background: Diabetic patients have an increased risk of bone fractures. Patients with type 1 DM are seven times more likely to suffer a fracture than those without DM, whereas those with type 2 DM are 1.3 times more likely to do so. Patients with T2DM have an increased risk for fractures, despite having a normal to increased bone mineral density, suggesting that other factors besides bone quantity must account for increased bone fragility. Objective: The aim of the current work was to assess fracture risk among diabetics who use glucose-lowering drugs. Methods: Fracture Risk, Glucose-Lowering Drugs, and diabetics were all looked for in PubMed, Google scholar, and ScienceDirect. References from relevant literature were also evaluated by the authors, but only the most recent or complete study from February 2016 to August 2022 was included. Due to the lack of sources for translation, documents in languages other than English have been ruled out. Papers that did not fall under the purview of major scientific investigations, such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations, were omitted. Conclusion: Some of the newer glucose-lowering therapies for type 2 diabetes have been shown to improve renal and cardiovascular outcomes. However, treatments aimed at reducing glucose levels may potentially influence fractures risks.
View on SCiNiTO
Top